SoftMedx Healthcare Limited (00648.HK) has issued a circular dated 10 Mar 2026 proposing the allotment and issue of 16.30 million new shares—termed “Scheme Shares”—to 25 scheme creditors under a Court-sanctioned restructuring scheme.
Key terms • Issue price: HK$0.01 per share, valuing the allotment at approximately HK$0.16 million. • Pricing discount: 96 % to the 10 Mar 2026 closing price of HK$0.28, and 97 % to both the five-day average price of HK$0.295 and the HK$0.38 close on 13 Dec 2023 (date of Court sanction). • Dilution: 0.77 % of issued share capital pre-issuance and 0.76 % post-issuance; theoretical dilution effect 1 %. When aggregated with the November 2025 new-share issue, cumulative dilution reaches 83 %. • Listing application: To be filed with the Stock Exchange after shareholder approval.
Specific mandate & conditions The Scheme Shares will be issued under a Specific Mandate requiring: 1) approval by ordinary resolution at the extraordinary general meeting (EGM); and 2) listing approval from the Stock Exchange.
Completion will occur within five business days after both conditions are met.
EGM details Date & time: 11:00 a.m., 30 Mar 2026 Format: live online webcast only; no physical attendance. Shareholders must appoint proxies to vote and register for the webcast by 28 Mar 2026. The register of members will be closed from 25 Mar to 30 Mar 2026.
Trust arrangement The new shares will first be allotted to Prohappy Enterprise Limited, which will hold them in trust for the scheme creditors and will not exercise voting rights before distribution.
Post-issuance shareholding snapshot • Multi Omniverse Group Limited: unchanged at 1,593.00 million shares, or 74.4 % of enlarged capital. • Scheme creditors: 16.30 million shares, 0.76 %. • Other public shareholders: 533.04 million shares, 24.9 %. Total shares will rise from 2,126.04 million to 2,142.34 million.
Background on the restructuring scheme • April 2023: Board resolved to pursue debt restructuring via a scheme of arrangement. • September 2023: Scheme approved at creditors’ meeting. • December 2023: Scheme sanctioned by the High Court of Hong Kong and became effective. • November 2025: Trading in SoftMedx shares resumed, triggering the obligation to issue Scheme Shares.
Recent fund-raising Aside from the conversion of HK$18.00 million loans into 1.80 billion new shares in November 2025, the company has conducted no other equity financing in the past 12 months; proceeds were fully applied to operating costs, trading resumption expenses and scheme implementation.
Business profile SoftMedx distributes medical and healthcare equipment and products in Hong Kong.